Anti-Human Carbonate dehydratase IX (CAIX) (Girentuximab) - 1.0 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Carbonic anhydrase IX (CAIX) is a type of transmembrane metalloenzyme that has asignificant role in maintaining the pH balance within cells. It is predominantly found in thegastrointestinal tract and gallbladder, where it facilitates acid secretion. In various types ofcancer, such as clear cell renal cell carcinoma (ccRCC), and breast, lung, and cervicalcancers, CAIX is often overexpressed in response to low oxygen levels (hypoxia) and islinked to a poor prognosis. CAIX contributes to the acidification of the surroundingenvironment, thereby promoting the growth and spread of tumors1-3. Girentuximab, also known as Rencarex, is a type of chimeric IgG1 monoclonal antibody thatis designed to target CAIX3. Researchers have been studying its potential in treating renalcell carcinoma (RCC) because it effectively targets CAIX, which is typically found in highlevels in most RCC cells. Girentuximab functions by initiating antibody-dependent cellularcytotoxicity (ADCC), destroying tumor cells that express CAIX. Despite the discontinuationof its development as a standalone antibody during phase III trials, scientists are stillexamining its use as a radioimmunoconjugate for both diagnostic and therapeutic applications4, 5.

≥ 5.0 mg/ml

CAIX is primarily expressed in the gastrointestinal tract andgallbladder. Its expression is significantly upregulated in various solid tumors, particularly inhypoxic environments.